Clinical trials: Chronic Hepatitis Delta
Chronic Hepatitis Delta
Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)
The primary objective of this study is to evaluate the efficacy of bulevirtide administered subcutaneously (SC) for 48 weeks at a dose of 2 mg or 10 mg once daily for treatment of chronic hepatitis delta (CHD) in comparison to…
- Trial name
- NCT03852719
- Testing
- Bulevirtide
- Where
- 19 sites in United States, Germany and 3 more
- Volunteers
- 150 people
- Sponsor
- Gilead Sciences
Hepatitis D, Hepatitis C
Evaluation of Patients With Liver Disease
The proposed study aims to evaluate, investigate, and follow-up patients suffering from acute and chronic liver disease. The study will focus on understanding diseases affecting the liver.
- Conditions
- Hepatitis D, Hepatitis C, Hepatitis B, Liver Disease
- Trial name
- NCT00001971
- Where
- United States
- Volunteers
- 8,050 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis D
Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis D
The goal of this clinical trial is to learn if drug RBD1016 works to treat chronic hepatitis D virus infection in adults. It will also learn about the safety of drug RBD1016.
- Trial name
- NCT06649266
- Testing
- RBD1016
- Where
- 2 sites in Sweden
- Volunteers
- 14 people
- Sponsor
- Ribocure Pharmaceuticals AB
Chronic Hepatitis Delta, Liver Biopsy
Study the Content of the HBV DNA in Liver Biopsy in the Patients Chronic Hepatitis Delta
Study the content of the HBV DNA in liver biopsy in the patients with the Chronic Hepatitis Delta in absence of the HBV DNA in the blood plasma
- Trial name
- NCT04170452
- Testing
- liver biopsy
- Where
- Uzbekistan
- Volunteers
- 30 people
- Sponsor
- Tokhirbek Dolimov
HBV, Fibrosis, Liver
Chronic Hepatitis B Virus Infection in Zambia
Chronic hepatitis B virus infection is a common condition in Zambia. Among Zambian blood donors, up to 8% are chronically infected with HBV.
- Conditions
- HBV, Fibrosis, Liver, Cirrhosis, Liver, Alcoholic Hepatitis
- Trial name
- HUTCH (NCT03158818)
- Testing
- Standard of care
- Where
- Zambia
- Volunteers
- 326 people
- Sponsor
- University of Alabama at Birmingham
Chronic HBV Infection (HBeAg Negative)
REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection
REP 2139-Ca is nucleic acid polymer. Nucleic acid polymers have been previously shown to clear serum hepatitis B virus surface antigen (HBsAg) both preclinically (in duck HBV infected ducks) and in human patients and to act…
- Trial name
- NCT02233075
- Testing
- REP 2139-Ca + Pegasys (TM)
- Where
- Moldova
- Volunteers
- 12 people
- Sponsor
- Replicor Inc.
Chronic Hepatitis D Infection
Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)
An Open-label, Dose-ranging Study to Evaluate the Safety and Efficacy of Lonafarnib with Ritonavir Boosting +/- Peginterferon alfa-2a in Patients Chronically Infected with Delta Hepatitis (HDV) (LOWR-2).
- Trial name
- LOWR-2 (NCT02430194)
- Testing
- lonafarnib, ritonavir, Pegylated interferon-alfa-2a
- Where
- Turkey (Türkiye)
- Volunteers
- 55 people
- Sponsor
- EIT Pharma, Inc.